Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study...

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• RAS and RAF mutations are implicated in skin carcinogenesis.
• Understanding mutation prevalence in melanoma and benign nequi is crucial for diagnosis and treatment.
• Assessing novel diagnostic technologies for mutation detection is essential.

Purpose of the Study:

• To evaluate the prevalence and roles of RAS and RAF mutations in melanoma, benign nevi, and normal skin.
• To compare the efficacy of digital droplet PCR (ddPCR) with existing methods for mutation detection.
• To explore the potential of ddPCR in clinical settings for analyzing skin lesion mutational profiles.

Main Methods:

• Utilized digital droplet PCR (ddPCR) and immunohistochemistry (IHC) for mutation analysis.
• Screened melanoma (n=22), benign nevi (n=15), and normal skin (n=15) samples.
• Assessed BRAF V600 and NRAS G12/G13 mutations and p16 protein expression.

Main Results:

• Coexistence of BRAF and NRAS mutations found in melanomas and nevi.
• NRAS G12/G13 variants detected in healthy skin samples.
• BRAF mutations correlated with Breslow index and TIL infiltration; NRAS mutations correlated with Breslow index and mitotic index.
• ddPCR demonstrated high sensitivity for detecting low-frequency mutations, comparable to CE-IVD methods.

Conclusions:

• ddPCR is a sensitive and effective method for detecting RAS and RAF mutations in skin lesions.
• The study identified specific mutation patterns associated with melanoma progression.
• ddPCR is recommended for broader clinical use in analyzing skin tumor mutations.